Evaxion Biotech A/S files Form 6-K on Feb 25, 2025, announcing an extension of its EVX-01 cancer vaccine trial. Key for growth and market positioning in biotech.
Discover Evaxion Biotech A/S's latest Form 6-K filed on February 14, 2025, detailing Nasdaq compliance and corporate transparency. Key insights on investor confidence and regulatory adherence.
Explore Evaxion Biotech A/S's latest Form 6-K report detailing capital increases, public offerings, and warrant grants, crucial for investors and stakeholders.
Discover Evaxion Biotech A/S's latest report on the successful completion of dosing in the phase 2 trial for EVX-01, an innovative personalized cancer vaccine. Key developments inside.
Evaxion Biotech A/S announces a new ADS to ordinary share ratio of 1:50 in its Form 6-K filing. Key details and regulatory compliance included.
Discover Evaxion Biotech A/S's significant shift in ADS ratio from 1:10 to 1:50, effective January 14, 2025. Understand implications for shareholders and market impact.
Explore Evaxion Biotech A/S's January 2025 Form 6-K filing revealing a DKK 11.47M share capital increase and warrant exercises. Key details on compliance and growth strategies.
Evaxion Biotech A/S updates investors on a new ADS ratio effective January 13, 2025, enhancing liquidity. Key details on exchange process and expected price movement included.
Explore Evaxion Biotech A/S's latest Form 6-K report detailing the January 17, 2025 Extraordinary General Meeting and important shareholder documentation.
Discover Evaxion Biotech A/S's latest Form 6-K report detailing debt conversion strategies and compliance efforts. Stay informed on AI-Immunology™ advancements and investor relations.